[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Seimiya YM, Takahashi M, Furukawa T, Mizutani K, Kimura K, Haritani M: An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma. J Vet Med Sci; 2009 Feb;71(2):225-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aged bull with concurrent thyroid C cell carcinoma, adrenal pheochromocytoma and pituitary chromophobe adenoma.
  • Pathological examination disclosed multiple endocrine tumors including thyroid C cell carcinoma with metastases to the cervical lymph nodes and lung, adrenal pheochromocytoma and pituitary chromophobe adenoma in the pars distalis.


2. Algaba F: Renal adenomas: pathological differential diagnosis with malignant tumors. Adv Urol; 2008;:974848

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal adenomas: pathological differential diagnosis with malignant tumors.
  • The renal adenomas can be confused by imaging diagnosis with malignant renal tumors, but there are also real biological dilemmas to determine their behavior.
  • The consensus decisions are the following. (1) The adenoma of clear cells is not accepted, instead it is considered that all the clear-cell tumors are carcinomas, with greater or lesser aggressiveness. (2) Among the papillary neoplasms the WHO 2004 renal cell tumors classification are considered as papillary adenomas tumors with a maximum diameter of 5 mm and may represent a continuum biological process to papillary renal cell carcinoma.
  • The papillary adenomas associated with End-kidney and/or acquired cystic disease may have a different pathogenesis. (3) To consider a tumor as an oncocytoma the size is not important, only the cytological features, microscopic, ultrastructural, and immunohistochemically can help, but some chromosomal observations introduce some questions about its relation with the chromophobe renal cell carcinoma. (4) Finally, the metanephric adenoma, a tumor with some morphological similarity with the nephroblastoma must be considered in the renal adenomas diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 2007 Aug;21(8):819-23 [17867935.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):239-46 [17056094.001]
  • [Cites] Urology. 2006 Oct;68(4):737-40 [17070344.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):218-24 [16424894.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):217-22 [16393684.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1275-9 [16287444.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 1;152(1):23-8 [15193438.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):101-4 [11172302.001]
  • (PMID = 18846240.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2563151
  •  go-up   go-down


3. Minami I, Tateno T, Yoshimoto T, Doi M, Izumiyama H, Akashi T, Hirata Y: Subclinical Cushings disease with amelioration of metabolic comorbidities after removal of pituitary tumor. Intern Med; 2006;45(21):1231-5
MedlinePlus Health Information. consumer health - Weight Loss Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclinical Cushings disease with amelioration of metabolic comorbidities after removal of pituitary tumor.
  • A 49-year-old woman with hypertension, obesity and impaired glucose tolerance (IGT) was admitted for evaluation of pituitary incidentaloma.
  • Although she presented no Cushingoid feature, endocrine examination of hypothalamo-pituitary-adrenal (HPA) axis showed elevated basal plasma ACTH and cortisol levels, their lack of circadian rhythm, non-suppressibility to low-dose (1 mg) dexamethasone, and responsiveness to CRH, suggesting autonomous ACTH secretion from a pituitary tumor.
  • She underwent transsphenoidal surgery, and was diagnosed as chromophobe adenoma with positive ACTH immunoreactivity.
  • Thus, her metabolic comorbidities are likely due to subclinical Cushings disease.
  • [MeSH-major] Glucose Intolerance / surgery. Hypertension / surgery. Obesity / surgery. Pituitary ACTH Hypersecretion / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Middle Aged. Pituitary-Adrenal System / metabolism. Pituitary-Adrenal System / surgery

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139124.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Ruggeri RM, Santarpia L, Curtò L, Torre ML, Galatioto M, Galatioto S, Trimarchi F, Cannavò S: Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. J Endocrinol Invest; 2008 Nov;31(11):946-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations.
  • BACKGROUND: Mutations of the genes encoding the alpha subunit of the stimulatory G protein (Gs) and of the inhibiting Gi2 protein (GNAS1 and GNAI2 genes, respectively) have been described in various endocrine neoplasias, including pituitary tumors.
  • AIM: To search for mutations of GNAS1 and GNAI2 in a continuous series of non-functioning pituitary adenoma (NFPA) patients neurosurgically treated.
  • CONCLUSIONS: This finding suggests and confirms that G-protein mutations are rare and not crucial in NFPA development.
  • [MeSH-major] Adenoma, Acidophil / genetics. Adenoma, Chromophobe / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. Intracellular Signaling Peptides and Proteins / genetics. Pituitary Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169048.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Codon; 0 / Intracellular Signaling Peptides and Proteins; 0 / URI1 protein, human; EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


5. Kozłowska J, Okoń K: Renal tumors in postmortem material. Pol J Pathol; 2008;59(1):21-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal tumors include several categories, the most frequent being clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe carcinoma, oncocytoma, adenoma and angiomyolipoma.
  • The most frequent diagnosis was adenoma (53 cases, 49.1%) and, among cancers, clear cell carcinoma (20 cases, 21.1%) followed by papillary carcinoma (17 cases, 15.5%).
  • The adenomas were significantly more frequent in cases of kidneys with chronic fibrosis.
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Female. Humans. Male. Middle Aged. Poland / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655367.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


6. Szponar A, Yusenko MV, Kovacs G: High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes. Histopathology; 2010 Jan;56(2):212-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes.
  • AIMS: Previous karyotyping and fluorescence in situ hybridization analysis of metanephric adenomas (MAs) has yielded controversial data.
  • METHODS AND RESULTS: DNA extracted from paraffin blocks of six metanephric adenomas was hybridized onto Agilent oligoarrays with approximately 43,000 in situ synthesized 60-mer oligonucleotide probes that span coding and non-coding sequences with an average spatial resolution of approximately 35 kb.
  • None of the metanephric adenomas showed DNA copy number changes.
  • To confirm our results, DNA extracted from the paraffin block of a chromophobe renal cell carcinoma (RCC) was simultaneously hybridized to one of the four arrays on the same slides as an internal control.
  • The chromophobe RCC showed loss of several chromosomes but no alteration was seen in MAs.
  • CONCLUSIONS: Our high-resolution oligoarray analysis indicates that metanephric adenomas lack DNA copy number alterations.
  • This finding may help to differentiate between metanephric adenomas from Wilms' tumour and papillary renal cell adenoma with overlapping phenotype.
  • [MeSH-major] Adenoma / genetics. DNA Copy Number Variations. Kidney Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102400.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Brown RL, Muzzafar T, Wollman R, Weiss RE: A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol; 2006 May;154(5):639-43
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry.
  • To our knowledge, only one case of a TSH-secreting carcinoma has previously been reported.
  • We describe here a second patient with a pituitary carcinoma producing TSH and prolactin (PRL).
  • Pathologic examination revealed a chromophobe adenoma with increased mitotic forms.
  • The patient completed a course of external beam radiation to the pituitary and was prescribed l-thyroxine, bromocriptine, and hydrocortisone.
  • Emergent resection of the larger mass revealed a pituitary cancer with positive staining for PRL, but not for TSH.
  • Nine months later, the patient underwent further debulking of metastatic disease.
  • Although development of a carcinoma from a pituitary adenoma is very rare (<0.5%), macroadenomas that become hormonally active should be suspect for transformation into pituitary cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645009.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK07011; United States / NCRR NIH HHS / RR / RR00055; United States / NCRR NIH HHS / RR / RR18372
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin
  •  go-up   go-down


8. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S: Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol; 2010 Dec;134(6):873-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated its immunohistochemical expression in 317 primary and 42 metastatic renal neoplasms (186 clear cell, 52 papillary, 35 chromophobe, 47 unclassified, and 15 Xp11.2 translocation renal cell carcinomas [RCCs]; 26 oncocytomas; 2 metanephric adenomas; 1 urothelial carcinoma; 1 mixed epithelial and stromal tumor; and 1 angiomyolipoma); 7 neoplasms were unknown as to whether they were primary or metastatic.
  • One chromophobe carcinoma had focal expression.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Med Oncol. 2009;26 Suppl 1:18-22 [19165638.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):750-61 [12766578.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):2-7 [12838292.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1398-403 [12854129.001]
  • [Cites] Urol Clin North Am. 2003 Nov;30(4):843-52 [14680319.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S [15448019.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):489-94 [2428759.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] J Urol. 1999 Feb;161(2):381-6; discussion 386-7 [9915408.001]
  • [Cites] Curr Oncol Rep. 2005 Mar;7(2):109-15 [15717944.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):640-6 [15832088.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):247-57 [15848735.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):51-68 [16512599.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5):534-43 [17045082.001]
  • [Cites] Histopathology. 2006 Dec;49(6):594-602 [17163844.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):225-9 [17210525.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4757-64 [17947723.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):241-7 [18941400.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • (PMID = 21088149.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA101942; United States / NCI NIH HHS / CA / P50CA101942
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ NIHMS511251; NLM/ PMC3778911
  •  go-up   go-down


9. Chung TT, Evanson J, Walker D, Akker SA, Besser GM, Monson JP, Grossman AB, Drake WM: Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. Clin Endocrinol (Oxf); 2008 Jun;68(6):965-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
  • BACKGROUND: Published data suggest that growth hormone replacement (GHR) may be given safely to patients with hypopituitarism consequent upon a pituitary/peripituitary tumour.
  • However, a preponderance of patients treated with external pituitary irradiation were included.
  • OBJECTIVE: To assess the safety of GHR in nonirradiated pituitary/peripituitary tumour.
  • PATIENTS: We imaged prospectively the pituitary glands of 48 patients (18 males; mean age 51.6 years range 21-77) who had adult onset growth hormone deficiency (AO-GHD) after appropriate treatment for a pituitary/peripituitary tumour but who did not receive external pituitary irradiation.
  • Pituitary surveillance imaging was performed prior to the commencement of GHR, at 6-12 months and then yearly.
  • Three patients were judged to have an apparent increase in tumour volume and/or marker, although only one was thought to be possibly GH related--a patient with a cystic chromophobe adenoma who demonstrated a marginal increase in residual tumour volume 4 years after commencement of GHR.
  • CONCLUSION: These data add to the growing body of evidence for the safety of GHR in hypopituitary patients consequent upon pituitary/peripituitary mass lesions and represents the first reported series in a heterogeneous group of nonirradiated patients.
  • [MeSH-major] Human Growth Hormone / adverse effects. Human Growth Hormone / therapeutic use. Hypopituitarism / drug therapy. Pituitary Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031317.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


10. Zhang J, Lefkowitz RA, Ishill NM, Wang L, Moskowitz CS, Russo P, Eisenberg H, Hricak H: Solid renal cortical tumors: differentiation with CT. Radiology; 2007 Aug;244(2):494-504
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To retrospectively determine if solid renal cortical tumors can be differentiated on computed tomographic (CT) images on the basis of their morphologic features and enhancement patterns.
  • RESULTS: Of the 198 renal tumors (median size, 3.4 cm; range, 1.1-20.0 cm) included in this study, 108 (55%) were clear cell renal cell carcinomas (RCCs); 30 (15%), papillary lesions; 24 (12%), chromophobe adenomas; 14 (7%), oncocytomas; six (3%), lipid-poor angiomyolipomas; and 16 (8%), other or unclassified renal tumors.
  • This pattern was highly predictive of clear cell RCC (odds ratio of 22 and 54 for readers 1 and 2, respectively, for comparison with homogeneous pattern), whereas the homogeneous and peripheral enhancing patterns were more predictive of less aggressive papillary and chromophobe lesions.
  • Clear cell RCCs and oncocytomas tended to be hypervascular, chromophobe lesions and angiomyolipomas tended to enhance moderately, and papillary lesions were mostly hypovascular.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641370.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


11. Wang KL, Weinrach DM, Luan C, Han M, Lin F, Teh BT, Yang XJ: Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma. Hum Pathol; 2007 Feb;38(2):239-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
  • The purpose of this study is to determine the incidence, histomorphological features, and immunohistochemical features of papillary adenoma and elucidate its potential relationship to RCC.
  • Thirty-eight (7%) nephrectomy specimens showed histologic evidence of papillary adenoma.
  • Seven papillary adenomas (18%) occurred in the setting of acquired polycystic kidney disease (APKD), 6 in clear-cell RCCs, 3 in chromophobe RCCs, 2 in end-stage kidney disease, 1 in oncocytoma, 1 in angiomyolipoma, and 1 in renal schwannoma.
  • Furthermore, papillary adenomas were more commonly found in kidneys removed for PRCC (25%, 18/71) than in kidneys harboring clear-cell RCC (1.9%, 6/318).
  • Histomorphologically, papillary adenomas were characterized by varying proportions of papillae and tubules formed by cuboidal cells with scant basophilic cytoplasm similar to those in type 1 PRCC.
  • Adenomas associated with PRCC tend to be multiple in number (61% [11/18] of cases had >2 adenomas; mean, 5).
  • In contrast, 100% of papillary adenomas arising in other conditions had less than 2 adenomas.
  • Most of the adenomas (82%, 31/38) stained strongly for AMACR in a fashion similar to that of PRCC.
  • In this study of surgical specimens, the high coincidence, multifocality, and histologic and immunohistochemical similarities between papillary adenoma and PRCC suggest that the 2 are strongly associated and may represent a continuum of 1 biologic process.
  • In contrast, adenomas associated with APKD exhibit distinct morphological and immunohistochemical features and, therefore, may have an entirely different pathogenesis.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / pathology. Adenoma. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Angiomyolipoma / enzymology. Angiomyolipoma / pathology. Disease Progression. Female. Glutathione Transferase / analysis. Humans. Immunohistochemistry. Isoenzymes / analysis. Kidney / enzymology. Kidney / pathology. Kidney Failure, Chronic / enzymology. Kidney Failure, Chronic / pathology. Male. Middle Aged. Models, Biological. Polycystic Kidney Diseases / enzymology. Polycystic Kidney Diseases / pathology. Racemases and Epimerases / analysis

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056094.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase alpha; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


12. Tienari J, Lehtonen S, Lehtonen E: CD2-associated protein in human urogenital system and in adult kidney tumours. Virchows Arch; 2005 Apr;446(4):394-401
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Type-I papillary RCCs (n=4) and papillary adenomas (n=3) were negative.
  • Chromophobe RCCs (n=2), oncocytomas (n=3) and urothelial carcinomas (n=2) were moderately positive.
  • The results show that CD2AP displays a specific expression pattern in human urogenital organs and that distinct expression is shown in several types of kidney tumours but not in type-I papillary RCCs or in papillary adenomas.
  • [MeSH-major] Adenoma / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Proteins / metabolism. Urogenital System / metabolism. src Homology Domains / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785926.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / CD2-associated protein; 0 / Cytoskeletal Proteins; 0 / Proteins
  •  go-up   go-down






Advertisement